{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:39:33Z","timestamp":1784241573066,"version":"3.55.0"},"reference-count":59,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto de Salud Carlos III","award":["PT13\/0010\/0039"],"award-info":[{"award-number":["PT13\/0010\/0039"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Severe Uncontrolled Asthma (SUA) counts for more than 25% of cases of severe asthma. The main factors that impair the quality of life of these patients are high doses of oral corticosteroids, the presence of exacerbations, and reduced lung function. The objective of this study was to evaluate, in real life, the clinical improvement of patients with SUA treated with anti-interleukin 5 (IL5) therapies: mepolizumab and benralizumab, together with the search for biomarkers associated with the response. We conducted a retrospective observational cohort study that included patients with severe uncontrolled eosinophilic asthma in a tertiary hospital receiving biological therapies. Three types of response were evaluated: improvement in lung function, reduction in exacerbations, and decrease in the use of oral corticosteroids. After 12 months of treatment, significant reductions were found in the number of exacerbations, the use of oral corticosteroids, and blood eosinophil levels for both biological therapies (p &lt; 0.001). Lung function improved, achieving a significant improvement in %FEV1 (p &lt; 0.001), as well as asthma control, with a significant increase in asthma control test (ACT) scores in both therapies. The markers associated with the corticosteroid-saving effect were the low doses of oral corticosteroids and absence of exacerbations for mepolizumab, and higher blood eosinophilia, absence of chronic obstructive pulmonary disease (COPD), and reduction in oral corticosteroid cycles for benralizumab. The greatest improvement in lung function in both therapies was linked to lower previous FEV1 levels and absence of other respiratory diseases. The reduction in exacerbations was associated with absence of exacerbations the previous year for mepolizumab and never smokers for benralizumab. The results of this real-life study confirm the clinical benefit obtained after the introduction of an anti-IL5 biological therapy and the possible predictive biomarkers of response to treatment.<\/jats:p>","DOI":"10.3390\/ijms24032011","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T07:57:38Z","timestamp":1674115058000},"page":"2011","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of Anti-IL5 Therapies on Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6930-8933","authenticated-orcid":false,"given":"Susana","family":"Rojo-Tolosa","sequence":"first","affiliation":[{"name":"Respiratory Medicine Department, University Hospital Virgen de las Nieves, 18014 Granada, Spain"},{"name":"Pharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Gonz\u00e1lez-Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Department, University Hospital Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Jim\u00e9nez-G\u00e1lvez","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Department, University Hospital Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"S\u00e1nchez-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Department, University Hospital Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5111-3895","authenticated-orcid":false,"given":"Laura Elena","family":"Pineda-Lancheros","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9225-8225","authenticated-orcid":false,"given":"Jos\u00e9 Mar\u00eda","family":"G\u00e1lvez-Navas","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, 18014 Granada, Spain"},{"name":"Center of Biomedical Research, Department of Biochemistry and Molecular Biology II, Institute of Nutrition and Food Technology \u201cJos\u00e9 Mataix\u201d, University of Granada, Avda. del Conocimiento s\/n., 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Jim\u00e9nez-Morales","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"P\u00e9rez-Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Center of Biomedical Research, Department of Biochemistry and Molecular Biology II, Institute of Nutrition and Food Technology \u201cJos\u00e9 Mataix\u201d, University of Granada, Avda. del Conocimiento s\/n., 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Morales-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Department, University Hospital Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"ref_1","unstructured":"(2020). GEMA 5.2. Gu\u00eda Espa\u00f1ola para el Manejo del Asma, Luz\u00e1n 5 Health Consulting, S.A."},{"key":"ref_2","unstructured":"(2022). GINA Committee Global Strategy for Asthma Management and Prevention 2022 Update. Glob. Initiat. Asthma, 225."},{"key":"ref_3","unstructured":"GBD 2019 Diseases and Injuries Collaborators (2020). Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990\u20132019: A Systematic Analysis for the Global Burden of Disease Study 2019. Lancet, 396, 1204\u20131222."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"114112","DOI":"10.1016\/j.bcp.2020.114112","article-title":"The Management of Severe Asthma in 2020","volume":"179","author":"Godbout","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1183\/09031936.03.00261903","article-title":"The ENFUMOSA Cross-Sectional European Multicentre Study of the Clinical Phenotype of Chronic Severe Asthma","volume":"22","author":"Abraham","year":"2003","journal-title":"Eur. Respir. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2006.11.639","article-title":"Characterization of the Severe Asthma Phenotype by the National Heart, Lung, and Blood Institute\u2019s Severe Asthma Research Program","volume":"119","author":"Moore","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/thx.2010.137414","article-title":"Refractory Asthma in the UK: Cross-Sectional Findings from a UK Multicentre Registry","volume":"65","author":"Heaney","year":"2010","journal-title":"Thorax"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0091-6749(72)90131-5","article-title":"Complications of Long-Term Steroid Therapy for Asthma","volume":"49","author":"Lieberman","year":"1972","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","article-title":"Mechanisms Involved in the Side Effects of Glucocorticoids","volume":"96","author":"Asadullah","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1136\/thx.2005.045195","article-title":"Asthma Exacerbations \u00b7 4: Prevention","volume":"61","author":"FitzGerald","year":"2006","journal-title":"Thorax"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0091-6749(97)70082-4","article-title":"Measuring Airway Inflammation in Asthma: Eosinophils and Eosinophilic Cationic Protein in Induced Sputum Compared with Peripheral Blood","volume":"99","author":"Pizzichini","year":"1997","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/ajrccm.161.1.9809100","article-title":"Changes in Sputum Eosinophils Predict Loss of Asthma Control","volume":"161","author":"Jatakanon","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/thx.54.2.108","article-title":"Effect of Differing Doses of Inhaled Budesonide on Markers of Airway Inflammation in Patients with Mild Asthma","volume":"54","author":"Jatakanon","year":"1999","journal-title":"Thorax"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma Exacerbations and Sputum Eosinophil Counts: A Randomised Controlled Trial","volume":"360","author":"Green","year":"2002","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(99)01813-9","article-title":"Non-Eosinophilic Cor Ticosteroid Unresponsive Asthma","volume":"353","author":"Pavord","year":"1999","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1034\/j.1399-3003.1999.14a04.x","article-title":"Montelukast Reduces Airway Eosinophilic Inflammation in Asthma: A Randomized, Controlled Trial","volume":"14","author":"Pizzichini","year":"1999","journal-title":"Eur. Respir. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1183\/09031936.05.00037905","article-title":"Risk Factors of Frequent Exacerbations in Difficult-to-Treat Asthma","volume":"26","author":"Sterk","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/all.12275","article-title":"EAACI Position Statement on Asthma Exacerbations and Severe Asthma","volume":"68","author":"Custovic","year":"2013","journal-title":"Allergy"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1164\/ajrccm.161.5.9903102","article-title":"Asthma","volume":"161","author":"Bousquet","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/thorax.55.1.19","article-title":"Risk Factors and Costs Associated with an Asthma Attack","volume":"55","author":"Hoskins","year":"2000","journal-title":"Thorax"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.rmed.2005.06.012","article-title":"An International Observational Prospective Study to Determine the Cost of Asthma Exacerbations (COAX)","volume":"100","author":"Lane","year":"2006","journal-title":"Respir. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40264-020-00926-3","article-title":"Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab","volume":"43","author":"Jackson","year":"2020","journal-title":"Drug Saf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/17476348.2020.1739526","article-title":"Benralizumab: An Updated Treatment of Eosinophilic Asthma","volume":"14","author":"Cushen","year":"2020","journal-title":"Expert. Rev. Respi. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1172\/JCI17974","article-title":"Anti-IL-5 Treatment Reduces Deposition of ECM Proteins in the Bronchial Subepithelial Basement Membrane of Mild Atopic Asthmatics","volume":"112","author":"Phipps","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1067\/mai.2003.1382","article-title":"Anti\u2013IL-5 (Mepolizumab) Therapy Induces Bone Marrow Eosinophil Maturational Arrest and Decreases Eosinophil Progenitors in the Bronchial Mucosa of Atopic Asthmatics","volume":"111","author":"Sehmi","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an Interleukin-5 Blocking Monoclonal Antibody on Eosinophils, Airway Hyper-Respons\u00ecveness, and the Late Asthmatic Response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/thx.2006.066837","article-title":"External Validity of Randomised Controlled Trials in Asthma: To Whom Do the Results of the Trials Apply?","volume":"62","author":"Travers","year":"2007","journal-title":"Thorax"},{"key":"ref_29","first-page":"1","article-title":"Real-Life Experience with Benralizumab during 6 Months","volume":"20","author":"Olveira","year":"2020","journal-title":"BMC Pulm. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-World Effectiveness and the Characteristics of a \u2018Super-Responder\u2019 to Mepolizumab in Severe Eosinophilic Asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","article-title":"Real World Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study","volume":"81","author":"Cabrerizo","year":"2021","journal-title":"Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/cea.14112","article-title":"Real-world Efficacy of Treatment with Benralizumab, Dupilumab, Mepolizumab and Reslizumab for Severe Asthma: A Systematic Review and Meta-analysis","volume":"52","author":"Charles","year":"2022","journal-title":"Clin. Exp. Allergy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1902420","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab Effectiveness and Identification of Super-Responders in Severe Asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of Effect and Impact on Health-Related Quality of Life, Exacerbation Rate, Lung Function, and Nasal Polyposis Symptoms for Patients with Severe Eosinophilic Asthma Treated with Benralizumab (ANDHI): A Randomised, Controlled, Phase 3b Trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/all.14235","article-title":"Efficacy and Safety of Treatment with Biologicals (Benralizumab, Dupilumab and Omalizumab) for Severe Allergic Asthma: A Systematic Review for the EAACI Guidelines - Recommendations on the Use of Biologicals in Severe Asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and Safety of Treatment with Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma. A Systematic Review for the EAACI Guidelines - Recommendations on the Use of Biologicals in Severe Asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of Mepolizumab Add-on Therapy on Health-Related Quality of Life and Markers of Asthma Control in Severe Eosinophilic Asthma (MUSCA): A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase 3b Trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet. Respir. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an Anti-Interleukin-5 Receptor \u03b1 Monoclonal Antibody, as Add-on Treatment for Patients with Severe, Uncontrolled, Eosinophilic Asthma (CALIMA): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and Safety of Benralizumab for Patients with Severe Asthma Uncontrolled with High-Dosage Inhaled Corticosteroids and Long-Acting \u03922-Agonists (SIROCCO): A Randomised, Multicentre, Placebo-Controlled Phase 3 Trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1080\/02770903.2021.2008431","article-title":"Real-Life Effectiveness of Mepolizumab in Severe Asthma: A Systematic Literature Review","volume":"59","author":"Israel","year":"2021","journal-title":"J. Asthma"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"100462","DOI":"10.1016\/j.waojou.2020.100462","article-title":"Real-Life Effectiveness of Mepolizumab in Patients with Severe Refractory Eosinophilic Asthma and Multiple Comorbidities","volume":"13","author":"Crimi","year":"2020","journal-title":"World Allergy Organ. J."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Maglio, A., Vitale, C., Pellegrino, S., Calabrese, C., D\u2019amato, M., Molino, A., Pelaia, C., Triggiani, M., Pelaia, G., and Stellato, C. (2021). Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma. Biomedicines, 9.","DOI":"10.3390\/biomedicines9111550"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"101946","DOI":"10.1016\/j.pupt.2020.101946","article-title":"Effectiveness of Mepolizumab Therapy in Patients with Severe Eosinophilic Asthma: Austrian Real-Life Data","volume":"64","author":"Renner","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.pulmoe.2021.05.007","article-title":"Mepolizumab for Severe Eosinophilic Asthma\u2013A One-Year Real Life Portuguese Study","volume":"27","author":"Paulino","year":"2021","journal-title":"Pulmonology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jaci.2015.05.039","article-title":"Blood Eosinophil Counts Predict Treatment Response in Patients with Severe Eosinophilic Asthma","volume":"136","author":"Ortega","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaci.2017.10.005","article-title":"Biomarkers for Severe Eosinophilic Asthma","volume":"140","author":"Yancey","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_50","first-page":"1","article-title":"Real-Life Cost-Effectiveness of Benralizumab in Patients with Severe Asthma","volume":"22","author":"Olveira","year":"2021","journal-title":"Respir. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.18176\/jiaci.0599","article-title":"Benralizumab in Real Life","volume":"31","year":"2021","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4081\/mrm.2021.785","article-title":"Real World Effectiveness of Benralizumab on Respiratory Function and Asthma Control","volume":"16","author":"Menzella","year":"2021","journal-title":"Multidiscip. Respir. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"631660","DOI":"10.3389\/fphar.2021.631660","article-title":"Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience","volume":"12","author":"Scioscia","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_54","first-page":"496","article-title":"Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma (Efectividad en el mundo real de benralizumab en el asma eosinof\u00edlica grave)","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Cofre"},{"key":"ref_55","unstructured":"(2022, July 05). Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios FICHA TECNICA Nucala 100 Mg Polvo Para Solucion Inyectable. Available online: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1151043001\/FT_1151043001.html."},{"key":"ref_56","unstructured":"(2022, July 05). Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios Ficha Tecnica Fasenra 30 Mg Solucion Inyectable En Jeringa Precargada. Available online: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1171252001\/FT_1171252001.html."},{"key":"ref_57","unstructured":"World Health Organization (2022, December 26). Obesity and Overweight. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1046\/j.1365-2796.2003.01219.x","article-title":"Corticosteroid Use and Risk of Hip Fracture: A Population-Based Case\u2013Control Study in Denmark","volume":"254","author":"Vestergaard","year":"2003","journal-title":"J. Intern. Med."},{"key":"ref_59","unstructured":"(2022, May 28). Asthma Control Test (ACT). Available online: https:\/\/www.thoracic.org\/members\/assemblies\/assemblies\/srn\/questionaires\/act.php."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2011\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:10:45Z","timestamp":1760119845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":59,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24032011"],"URL":"https:\/\/doi.org\/10.3390\/ijms24032011","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]}}}